FARRAGUT PARTNERS LLP

Lobbying for GENENTECH · Biotechnology

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · District of Columbia · House · Senate · $50,000.00 income · posted Jan 20, 2026

Lobbying activity 2

Medicare/Medicaid

Issues regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program. Drug Pricing Proposals. CMMI Guardrails. Issues related to drug pricing (IPI, Part B reforms). 21st century cures 2.0 legislation.

Health Issues

Issues related to the 340B Drug discount program. Drug Pricing Proposals. Issues related to drug pricing. 21st century cures 2.0 legislation.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.